RED - approved for use via the COVID Medicines Delivery Unit, in 'highest' risk non-hospitalised patients with COVID-19 in accordance with current NHSE commissioning policy.
Molnupiravir is restricted for supply via secondary care (CMDU). Further information on the oral antiviral can be found here.